Marvel Biosciences Announces Stock Option Grants

Calgary, Alberta, Canada, September 26, 2022 – Marvel Biosciences Corp. (TSX-V: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company” or “Marvel”), today announced that its board of directors has approved the grant of...

Marvel Biosciences Corp. Closes Second Tranch of Private Placement

Calgary, Alberta, Canada, August 9, 2022 – Marvel Biosciences Corp. (TSX-V: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company” or“Marvel”), is pleased to report that, further to its news releases of June 21, 2022 and...

Marvel Biosciences Closes First Tranche of Private Placement

Calgary, Alberta, Canada, July 18, 2022 – Marvel Biosciences Corp. (TSX-V: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company” or “Marvel”), is pleased to report that, further to its news release of June 21, 2022, it has...